Source: PR Newswire ALPHAEON Corporation (www.alphaeon.com) today announced that its wholly-owned subsidiary, Evolus Inc., submitted a Biologics License Application (BLA) for DWP-450, a Botulinum toxin Type A, to the U.S. Food and Drug Administration (FDA) seeking approval for the treatment of adult patients with glabellar lines, also known as "frown…...

Source: FierceBiotech Sienna Biopharmaceuticals has raised $40 million to advance its pipeline of clinical-phase aesthetic and dermatology assets. The Series B round continues the rapid rise of Sienna, which has raised $86 million and bought Creabilis since it emerged helmed by the ex-Kythera Biopharmaceuticals team last year. Westlake Village, California-based Sienna…...

Source: FierceBiotech Cardinal Health will acquire Medtronic’s Patient Care, Deep Vein Thrombosis and Nutritional Insufficiency units for $6.1 billion in cash in a deal slated to close in the quarter ending Sept. 30. The healthcare services company will gain 10,000 employees and a range of products, including the Kangaroo suite…...

Source: LinkedIn I’m sure you’ve been asked many times whether you’re an introvert or an extrovert. For some people, it’s an easy choice, but for most of us, it’s difficult to choose one way or the other. It’s hard to choose because the introvert/extrovert dichotomy reflects a tired and outdated…...

Source: FierceBiotech Allergan and partner Paratek Pharmaceuticals have hit their primary endpoints in two key phase 3 acne trials for their investigational med sarecycline. The pair will now seek an FDA NDA in the second half of the year after the two “replicative” late-stage tests that saw the med outdo…...

Source: Cipher Pharmaceuticals Inc. (CPH.TO) ("Cipher" or "the Company") announced today that veteran pharmaceutical industry executive Robert D. Tessarolo has been appointed President and Chief Executive Officer of Cipher, effective April 17 , 2017. Mr. Tessarolo will also be nominated for election as a director at the Company's next annual…...

Source: Sun Pharmaceutical Industries today said an indirect arm of its group firm Taro will fully acquire Canada’s Thallion Pharmaceuticals for 2.7 million Canadian dollar. Taro Pharmaceuticals Inc (Canada) has entered into an agreement to acquire all of the issued and outstanding shares of Thallion Pharmaceuticals, a Canadian pharmaceutical corporation,…...

Source: Novan MORRISVILLE, N.C., March 06, 2017 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (NASDAQ:NOVN) today announced that, after further analysis of the results from the NI-AC301 and NI-AC302 pivotal clinical trials for the Company’s topical nitric oxide-releasing product candidate, SB204, it intends to proceed with the SB204…...

Source: Since its massive Pfizer merger fell through last year, Allergan has persisted with “stepping-stone deals” rather than a transformational buy. Monday, the drugmaker unveiled its latest buy, Zeltiq, a $2.47 billion add-on for its aesthetics business. With Zeltiq, Allergan will get the sales leader in body contouring—read fat-fighting—and a…...

Source: Business Wire Encore Dermatology Inc., a privately held dermatology company that specializes in developing and commercializing novel prescription products for improving skin health, announced today the availability of TridesilonTM (desonide) Cream, 0.05% in a 60g tube. TridesilonTM Cream, 0.05% is a low-potency corticosteroid indicated for the relief of the…...